1993PubMedRequires access

A study of the interrelationship between circulating IgG subclass anti-IgE autoantibodies, IgE and soluble CD23 in asthma.

Farouk Shakib, L Boulstridge, Smith Sj

Open publisher page 10 citations

Abstract

In this paper we hypothesise that circulating autoanti-IgE antibodies, which are found in allergic asthma patients, could potentially enhance IgE synthesis by blocking its binding to CD23 on B lymphocytes, thereby potentiating the release of soluble fragments of CD23 which have B cell growth-promoting activity. We have investigated this possibility indirectly by measuring soluble (s) CD23 and IgG subclass anti-IgE antibody levels in asthmatic patients' sera, to find out if the two parameters are related. However, we were unable to show any significant correlations between serum IgG subclass anti-IgE activities and sCD23 levels. This may have been due, at least in part, to the heterogeneous epitope specificity of the autoanti-IgE being detected. Interestingly, there was a significant inverse correlation (p = 0.0178) between serum IgE and sCD23 levels in asthma; an observation which underlines the notion that binding of IgE to membrane CD23 abrogates the release of sCD23. The present study confirms and extends previous reports of significantly raised circulating levels of IgG anti-IgE in asthma patients (p = 0.0004), by further demonstrating that IgG anti-IgE is mostly restricted to IgG1. Given that IgG1 binds very efficiently to C1q and Fc gamma Rs, our observation lends further support to the notion that IgG anti-IgE may facilitate the removal of IgE-allergen complexes by triggering IgG effector function pathways.

About this research paper

What this paper is about

In this paper we hypothesise that circulating autoanti-IgE antibodies, which are found in allergic asthma patients, could potentially enhance IgE synthesis by blocking its binding to CD23 on B lymphocytes, thereby potentiating the release of soluble fragments of CD23 which have B cell growth-promoting activity. We have investigated this possibility indirectly by measuring soluble (s) CD23 and IgG subclass anti-IgE antibody levels in asthmatic patients' sera, to find out if the two parameters are related. However, we were unable to show any significant correlations between serum IgG subclass anti-IgE activities and sCD23 levels. This may have been due, at least in part, to the heterogeneous epitope specificity of the autoanti-IgE being detected. Interestingly, there was a significant inverse correlation (p = 0.0178) between serum IgE and sCD23 levels in asthma; an observation which underlines the notion that binding of IgE to membrane CD23 abrogates the release of sCD23. The present study confirms and extends previous reports of significantly raised circulating levels of IgG anti-IgE in asthma patients (p = 0.0004), by further demonstrating that IgG anti-IgE is mostly restricted to IgG1. Given that IgG1 binds very efficiently to C1q and Fc gamma Rs, our observation lends further support to the notion that IgG anti-IgE may facilitate the removal of IgE-allergen complexes by triggering IgG effector function pathways.

Why it matters

OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In this paper we hypothesise that circulating autoanti-IgE antibodies, which are found in allergic asthma patients, could potentially enhance IgE synthesis by blocking its binding to CD23 on B lymphocytes, thereby potentiating the release of soluble fragments of CD23 which have B cell growth-promoting activity. We have investigated this possibility indirectly by measuring soluble (s) CD23 and IgG subclass anti-IgE antibody levels in asthmatic patients' sera, to find out if the two parameters are related. However, we were unable to show any significant correlations between serum IgG subclass anti-IgE activities and sCD23 levels. This may have been due, at least in part, to the heterogeneous epitope specificity of the autoanti-IgE being detected. Interestingly, there was a significant inverse correlation (p = 0.0178) between serum IgE and sCD23 levels in asthma; an observation which underlines the notion that binding of IgE to membrane CD23 abrogates the release of sCD23. The present study confirms and extends previous reports of significantly raised circulating levels of IgG anti-IgE in asthma patients (p = 0.0004), by further demonstrating that IgG anti-IgE is mostly restricted to IgG1. Given that IgG1 binds very efficiently to C1q and Fc gamma Rs, our observation lends further support to the notion that IgG anti-IgE may facilitate the removal of IgE-allergen complexes by triggering IgG effector function pathways.

Key concepts: CD23, Immunoglobulin E, Subclass, Immunology, Medicine, Antibody, Epitope, Asthma

Related papers

Back to paper searchBrowse research topicsOriginal source
A study of the interrelationship between circulating IgG subclass anti-IgE autoantibodies, IgE and soluble CD23 in asthma. — Research Paper | ScholarLens